東寶生物(300239.SZ):總經理王麗萍、董祕劉芳等三股東擬合計減持不超2.56%公司股份
格隆匯 9 月 30日丨東寶生物(300239.SZ)公佈,持股6.44%的股東內蒙古金融資產管理有限公司計劃自本公告發布之日起15個交易日後的六個月內以集中競價方式減持公司股份不超過1043.62萬股(佔公司總股本比例2%),且任意連續90個自然日內減持不超過公司股份總數的1%。
持股1.24%的董事、總經理王麗萍計劃自本公告發布之日起15個交易日後的六個月內以集中競價方式減持公司股份不超過158.54萬股(不超過其持有公司股份總數的25%,佔公司總股本比例0.3%)。
持股1.05%的董事、副總經理兼董事會祕書劉芳計劃自本公告發布之日起15個交易日後的六個月內以集中競價方式減持公司股份不超過133.9550萬股(不超過持有公司股份總數的25%,佔公司總股本比例0.26%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.